白内障合并糖尿病视网膜病变:超声乳化联合预防性玻璃体腔注射贝伐珠单抗的Meta分析
该Meta分析纳入6项比较研究共283眼,评估白内障手术联合玻璃体腔注射贝伐珠单抗(IVB)治疗合并糖尿病视网膜病变(DR)患者的疗效。结果显示IVB组术后1个月和3个月矫正远视力显著优于对照组,1、3、6个月黄斑中心厚度显著更薄,6个月时DR及黄斑病变进展在对照组更常见。结论认为联合IVB在短期(至6个月)似乎有效。
要点
- IVB组术后1个月和3个月矫正远视力显著优于对照组,6个月时两组无显著差异。
- IVB组术后1、3、6个月黄斑中心厚度均显著薄于对照组。
- 6个月时对照组术后DR和黃斑病变进展发生率显著高于IVB组。
核心结论
- 该Meta分析提示,白内障手术联合IVB对合并DR的患者在短期(至6个月)似乎是一种有效的治疗。
- 需要更多随机、前瞻性、大样本试验来评估白内障手术时IVB的长期效果。
研究设计与样本
- 通过系统检索PubMed、EMBASE和Cochrane对照试验注册库(截至2016年3月1日)纳入比较研究。
- 共纳入6项研究,合计283眼。
- 使用RevMan(Cochrane协作网,牛津,英国)进行Meta分析。
主要发现
- 术后1个月和3个月矫正远视力IVB组显著优于对照组(P < 0.00001和P = 0.01)。
- 术后6个月矫正远视力两组无显著差异(P = 0.24)。
- 术后1、3、6个月黄斑中心厚度IVB组显著薄于对照组(P = 0.01、P = 0.0004和P = 0.01)。
- 6个月时术后DR进展对照组较IVB组更常见(P = 0.0001)。
- 6个月时术后黄斑病变进展对照组较IVB组更常见(P < 0.0001)。
关键数值与推荐
- 结局指标包括矫正远视力、黄斑中心厚度、DR及黄斑病变进展。
- 术后1个月矫正远视力组间比较P < 0.00001,术后3个月P = 0.01,术后6个月P = 0.24。
- 术后1、3、6个月黄斑中心厚度组间比较P分别为0.01、0.0004、0.01。
- 6个月时DR进展组间比较P = 0.0001,黄斑病变进展组间比较P < 0.0001。
临床怎么用
- 对于合并DR的白内障患者,超声乳化手术联合预防性IVB在短期(至6个月)可能改善视力并减轻黄斑水肿、减少DR进展。
- 长期疗效尚需更多随机、前瞻性、大样本试验评估。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the clinical effectiveness of intravitreal bevacizumab (IVB) injection combined with cataract surgery in the treatment of patients with cataract and coexisting diabetic retinopathy (DR). METHODS: Pertinent comparative studies were identified through systemic searches of PubMed, EMBASE, and the Cochrane Controlled Trials Register up to March 1, 2016. Outcome measures included corrected distance vision acuity, central macular thickness, and progression of DR and maculopathy. A meta-analysis was performed using RevMan (Cochrane Collaboration, Oxford, United Kingdom). RESULTS: Six studies describing a total of 283 eyes were identified. The meta-analysis results showed that corrected distance vision acuity measured at 1 month and 3 months after cataract surgery was significantly better in the IVB groups than in the control groups (P < 0.00001 and P = 0.01), whereas the corrected distance vision acuity at 6 months did not vary significantly between the 2 groups (P = 0.24). Similarly, the central macular thickness at 1, 3, and 6 months after surgery was significantly thinner in the IVB groups than in the control groups (P = 0.01, P = 0.0004, and P = 0.01, respectively). At 6 months, the progression of postoperative DR and maculopathy occurred more frequently in the control group than in the IVB group (P = 0.0001 and P < 0.0001, respectively). CONCLUSION: Our meta-analysis indicates that cataract surgery combined with IVB seems to be an effective treatment in patients with coexisting DR in the short term (up to 6 months). More randomized, prospective, and large-sample-sized trials are needed to evaluate the long-term effects of IVB at the time of cataract surgery in patients with DR.
引用
- Feng Y, Zhu S, Skiadaresi E, et al. PHACOEMULSIFICATION CATARACT SURGERY WITH PROPHYLACTIC INTRAVITREAL BEVACIZUMAB FOR PATIENTS WITH COEXISTING DIABETIC RETINOPATHY: A Meta-Analysis. Retina. 2019. PMID: 29975344. doi:10.1097/IAE.0000000000002221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。